Jenny Guek Hong Low

Jenny Guek Hong Low

Auto-generated profile, based on publicly available information

Jenny Guek Hong Low

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, College Road, 169857, Singapore; Viral Research and Experimental Medicine Centre (ViREMiCS), SingHealth Duke-NUS Academic Medical Centre, 169856, Singapore; Department of Infectious Diseases, Singapore General Hospital, Outram Road, 169608, Singapore

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
NBNina Le Bert
Nina Le Bert
ATAnthony T. Tan
Anthony T. Tan
KKKamini Kunasegaran
Kamini Kunasegaran
CTChristine Y. L. Tham
Christine Y. L. Tham
MHMorteza Hafezi
Morteza Hafezi
ABAntonio Bertoletti
Antonio Bertoletti

1 March 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
NBNina Le Bert
Nina Le Bert
HCHannah Clapham
Hannah Clapham
ATAnthony T. Tan
Anthony T. Tan
WCWan Ni Chia
Wan Ni Chia
CTChristine Y.L. Tham
Christine Y.L. Tham
CTClarence C. Tam
Clarence C. Tam
The efficacy of virus-specific T cells in clearing pathogens involves a fine balance between antiviral and inflammatory features. SARS-CoV-2–specific T cells in individuals who clear SARS-CoV-2 without symptoms could reveal nonpathological yet protective characteristics. We longitudinally studied SARS-CoV-2–specific T cells in a cohort of asymptomatic (n = 85) and symptomatic (n = 75) COVID-19 patients after seroconversion. We quantified T cells reactive to structural proteins (M, NP, and Spike) using ELISpot and cytokine secretion in whole blood. Frequencies of SARS-CoV-2–specific T cells were similar between asymptomatic and symptomatic individuals, but the former showed an increased IFN-γ and IL-2 production. This was associated with a proportional secretion of IL-10 and proinflammatory cytokines (IL-6, TNF-α, and IL-1β) only in asymptomatic infection, while a disproportionate secretion of inflammatory cytokines was triggered by SARS-CoV-2–specific T cell activation in symptomatic individuals. Thus, asymptomatic SARS-CoV-2–infected individuals are not characterized by weak antiviral immunity; on the contrary, they mount a highly functional virus-specific cellular immune response.

1 June 2020 in Cell Host & Microbe
Verified
Journal Article
Closed access
EOEugenia Ziying Ong
Eugenia Ziying Ong
YCYvonne Fu Zi Chan
Yvonne Fu Zi Chan
WLWan Ying Leong
Wan Ying Leong
NLNatalie Mei Ying Lee
Natalie Mei Ying Lee
SKShirin Kalimuddin
Shirin Kalimuddin
JLJenny Guek Hong Low
Jenny Guek Hong Low

25 August 2020 in mBio
Verified
Journal Article
Open access
PDF file
YSYvonne Su
Yvonne Su
DADanielle Anderson
Danielle Anderson
BYBarnaby E. Young
Barnaby E. Young
MLMartin Linster
Martin Linster
FZFeng Zhu
Feng Zhu
GSGavin Smith
Gavin Smith
To date, limited genetic changes in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome have been described. Here, we report a 382-nucleotide (nt) deletion in SARS-CoV-2 that truncates open reading frame 7b (ORF7b) and ORF8, removing the ORF8 transcription regulatory sequence (TRS) and eliminating ORF8 transcription. The earliest 382-nt deletion variant was detected in Singapore on 29 January 2020, with the deletion viruses circulating in the country and accounting for 23.6% (45/191) of SARS-CoV-2 samples screened in this study. SARS-CoV-2 with the same deletion has since been detected in Taiwan, and other ORF7b/8 deletions of various lengths, ranging from 62 nt to 345 nt, have been observed in other geographic locations, including Australia, Bangladesh, and Spain. Mutations or deletions in ORF8 of SARS-CoV have been associated with reduced replicative fitness and virus attenuation. In contrast, the SARS-CoV-2 382-nt deletion viruses showed significantly higher replicative fitness in vitro than the wild type, while no difference was observed in patient viral load, indicating that the deletion variant viruses retained their replicative fitness. A robust antibody response to ORF8 has been observed in SARS-CoV-2 infection, suggesting that the emergence of ORF8 deletions may be due to immune-driven selection and that further deletion variants may emerge during the sustained transmission of SARS-CoV-2 in humans. IMPORTANCE During the SARS epidemic in 2003/2004, a number of deletions were observed in ORF8 of SARS-CoV, and eventually deletion variants became predominant, leading to the hypothesis that ORF8 was an evolutionary hot spot for adaptation of SARS-CoV to humans. However, due to the successful control of the SARS epidemic, the importance of these deletions for the epidemiological fitness of SARS-CoV in humans could not be established. The emergence of multiple SARS-CoV-2 strains with ORF8 deletions, combined with evidence of a robust immune response to ORF8, suggests that the lack of ORF8 may assist with host immune evasion. In addition to providing a key insight into the evolutionary behavior of SARS-CoV-2 as the virus adapts to its new human hosts, the emergence of ORF8 deletion variants may also impact vaccination strategies.

4 February 2017 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
JLJenny G. H. Low
Jenny G. H. Low
EOEng Eong Ooi
Eng Eong Ooi
SVSubhash G. Vasudevan
Subhash G. Vasudevan
Dengue is a significant global health problem. Even though a vaccine against dengue is now available, which is a notable achievement, its long-term protective efficacy against each of the 4 dengue virus serotypes remains to be definitively determined. Consequently, drugs directed at the viral targets or critical host mechanisms that can be used safely as prophylaxis or treatment to effectively ameliorate disease or reduce disease severity and fatalities are still needed to reduce the burden of dengue. This review will provide a brief account of the status of therapeutics research and development for dengue.

16 August 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JLJoey Ming Er Lim
Joey Ming Er Lim
ATAnthony Tanoto Tan
Anthony Tanoto Tan
NBNina Le Bert
Nina Le Bert
SHShou Kit Hang
Shou Kit Hang
JLJenny Guek Hong Low
Jenny Guek Hong Low
ABAntonio Bertoletti
Antonio Bertoletti
Rapid recognition of SARS-CoV-2–infected cells by resident T cells in the upper airway might provide an important layer of protection against COVID-19. Whether parenteral SARS-CoV-2 vaccination or infection induces nasal-resident T cells specific for distinct SARS-CoV-2 proteins is unknown. We isolated T cells from the nasal mucosa of COVID-19 vaccinees who either experienced SARS-CoV-2 infection after vaccination (n = 34) or not (n = 16) and analyzed their phenotype, SARS-CoV-2 specificity, function, and persistence. Nasal-resident SARS-CoV-2–specific CD8+ and CD4+ T cells were detected almost exclusively in vaccinees who experienced SARS-CoV-2 breakthrough infection. Importantly, the Spike-specific T cells primed by vaccination did not suppress the induction of T cells specific for other SARS-CoV-2 proteins. The nasal-resident T cell responses persisted for ≥140 d, with minimal sign of waning. These data highlight the importance of viral nasal challenge in the formation of SARS-CoV-2–specific antiviral immunity at the site of primary infection and further define the immunological features of SARS-CoV-2 hybrid immunity.